Oncopeptides AB, a Stockholm, Sweden-based company working to enhance oncology therapies, completed a Series A financing round.
The amount of the funding was not disclosed.
The round was led by HealthCap, with participation from existing investor Industrifonden, members of the management and Board. In conjunction with the funding, Per Samuelsson and Johan Christenson from HealthCap joined Oncopeptides’ Board of Directors.
Led by CEO Jakob Lindberg, Oncopeptides is a clinical stage pharmaceutical development company that aims to create cytosuperiors of existing basic cytotoxic compounds.
The company intends to use the capital to finance a phase II clinical program in multiple myeloma with the novel cytosuperior compound melflufen, an enhanced cytotoxic alkylating agent based on melphalan.